Phase i trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors

Journal of Clinical Pharmacology

Volumn 52, Issue 5, 2012, Pages 656-669

  Shacham Shmueli, Einat ^a,b   Geva, Ravit ^a   Figer, Arie ^b   Bulocinic, Sarah ^a   Nalbandyan, Karen ^a   Shpigel, Shulim ^a   Atsmon, Jacob ^a   Brendel, Erich ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAYER PHARMA AG   (Germany)

Author keywords

combination; drug therapy; Fluorouracil; solid tumors; sorafenib

Indexed keywords

FLUOROURACIL; FOLINIC ACID; SORAFENIB;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; COLON CANCER; DRUG TOLERABILITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; MAXIMUM PLASMA CONCENTRATION; PANCREAS CANCER; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BENZENESULFONATES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; ISRAEL; LEUCOVORIN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 84860311056     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011404027     Document Type: Article

References (43)

1. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist. 2005 ; 10: 40-48 (Pubitemid 43152729)
2. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989 ; 16: 215-237 (Pubitemid 19114713)
3. Kufe DW, Major PP. 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem. 1981 ; 256: 9802-9805 (Pubitemid 12176177)
4. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist. 2001 ; 6: 12-16 (Pubitemid 32954216)
5. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry. 1974 ; 13: 471-481
6. Kish JA, Wolf M, Crawford ED, et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer. 1994 ; 74: 916-919 (Pubitemid 24237473)
7. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol. 1992 ; 10: 896-903
8. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 ; 64: 7099-7109 (Pubitemid 39331023)
9. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res. 2003 ; 9: 3362-3368 (Pubitemid 37082731)
10. Levy JB, Pauloski N, Braun D, et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc Am Assoc Cancer Res. 2006 ; 47: 213-214
11. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005 ; 65: 2412-2421 (Pubitemid 40490153)
12. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 ; 98: 326-334 (Pubitemid 43338212)
13. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006 ; 66: 11851-11858 (Pubitemid 46094197)
14. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 ; 24: 6861-6869 (Pubitemid 41509409)
15. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005 ; 23: 965-972 (Pubitemid 46202316)
16. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 ; 356: 125-134 (Pubitemid 46089673)
17. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 ; 24: 2505-2512 (Pubitemid 46630627)
18. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 ; 27: 1280-1289
19. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 ; 359: 378-390
20. Montville, NJ: Bayer Healthcare Pharmaceuticals, Inc ; 2009:
21. medac GmbH. 5-FU Summary Product Characteristics. 2009. http://www.medicines.org.uk/emc/medicine/6378/spc/ fluorouracil+injection%2c+50+mg+++ml%2c+solution+for+injection+++(medac+UK)/. Accessed June10, 2010.
22. Vincent P, Zhang X, Chen C, et al. Chemotherapy with the raf kinase inhibitor BAY 43-9006 in combination with irinotecan, vinorelbine, or gemcitabine is well tolerated and efficacious in preclinical xenograft models [abstract]. Proc Am Soc Clin Oncol. 2002 ; 21: 1900
23. Heim M, Sharifi M, Hilger RA, Scheulen ME, Seeber S, Strumberg D. Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. Int J Clin Pharmacol Ther. 2003 ; 41: 616-617
24. Awada A, Hendlisz A, Gil T, et al. A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors [abstract 381]. Eur J Cancer. 2004 ; 2: 114
25. Kupsch P, Henning BF, Passarge K, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer. 2005 ; 5: 188-196
26. Mross K, Steinbild S, Baas F, et al. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int J Clin Pharmacol Ther. 2003 ; 41: 618-619
27. Richly H, Kupsch P, Passage K, et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther. 2004 ; 42: 650-651
28. Richly H, Kupsch P, Passarge K, et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors [abstract]. J Clin Oncol. 2004 ; 22: 3049
29. Siu L, Awada A, Takimoto CH. A phase I/II trial of BAY 43-9006 and gemcitabine in advance solid tumors and in advance pancreatic cancer [abstract 3059]. Proc Am Soc Clin Oncol. 2004 ; 23: 209
30. Pratt CB, Meyer WH, Howlett N, et al. Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. Cancer. 1994 ; 74: 2593-2598 (Pubitemid 24320867)
31. Eisen T, Ahmad T, Gore ME, et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients [abstract]. J Clin Oncol. 2005 ; 23: 7508
32. Flaherty KT, Redlinger M, Schuchter LM, Lathia CD, Weber BL, O'Dwyer PJ. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma [abstract 3037]. J Clin Oncol. 2005 ; 23: 201s
33. Siu LL, Awada A, Takimoto C, et al. Phase I study of oral Raf-1 kinase inhibitor BAY 43-9006 in combination with gemcitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 2003 ; 22: 828
34. Flaherty KT, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [abstract]. J Clin Oncol. 2004 ; 22: 7507
35. Eisen T, Ahmad T, Marais R, et al. Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma [abstract]. Eur J Cancer. 2005 ; 3: 349
36. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer. 2005 ; 92: 1855-1861 (Pubitemid 40826133)
37. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005 ; 11: 5472-5480 (Pubitemid 41060823)
38. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol. 2005 ; 16: 1688-1694 (Pubitemid 41510145)
39. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res. 2004 ; 91: 169-200 (Pubitemid 39140959)
40. Cornwell MM, Smith DE. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem. 1993 ; 268: 15347-15350 (Pubitemid 23222019)
41. Geney R, Ungureanu M, Li D, Ojima I. Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med. 2002 ; 40: 918-925 (Pubitemid 35277418)
42. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004 ; 9: 2-10 (Pubitemid 38747842)
43. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005 ; 69: 11-16 (Pubitemid 41680948)